Pimavanserin
Chemical compound
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth. Side effects of pimavanserin include peripheral edema and confusion.
Nº Q7194603 ★
Common · Knowledge
Pimavanserin
Chemical compound
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth. Side effects of pimavanserin include peripheral edema and confusion.
Last price
—
Floor price
—
7-day median
—
30-day sales
0
30-day range
—
In circulation
0
Price history
median
low – high
sales
No sales in this period
Show table
| Date | median | Low | High | sales |
|---|
Sales history
- Last sale
- —
- 30-day average
- —
- 30-day low
- —
- 30-day high
- —
- Sales 7d
- 0
- Sales 30d
- 0
No sales yet.
Anonymous sales: no buyer or seller shown. Figures count player-to-player sales only.
From Wikipedia
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis. It is taken by mouth. Side effects of pimavanserin include peripheral edema and confusion. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, but rather is a selective antagonist or inverse agonist of the serotonin 5-HT2A receptor and to a lesser extent of the serotonin 5-HT2C receptor. Pimavanserin was first approved for medical use in 2016. It was approved as a generic medication in 2024.
Text: Wikipédia, CC BY-SA 4.0. · Image: Vaccinationist (Public domain) ·
Related cards
-
Perphenazine
Antipsychotic medication
Nº Q423520 ★★
Not listed
-
Paliperidone
Chemical compound
Nº Q423292 ★★
Not listed
-
Blonanserin
Chemical compound
Nº Q4927426 ★
Not listed
-
Cinnarizine
Chemical compound
Nº Q775073 ★★★
Not listed
-
Pramipexole
Chemical compound
Nº Q421304 ★★
Not listed
-
Upadacitinib
Chemical compound
Nº Q27074125 ★★
Not listed